Quality by Design in Excipients - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Quality by Design in Excipients
Factors for assessing excipient variability, the associated challenges developers need to address to design and manufacture solid oral drug products, and solutions for such challenges are examined.

Pharmaceutical Technology
pp. s26-s28

Along with the specified parameters, it is important to also consider both unspecified parameters as well as nonroutine parameters. The variability of unspecified or unreported parameters, could impact drug-product performance depending upon its design and intended use. Although unreported, these properties may be measured by the manufacturer as part of its control strategy. In addition, excipients can vary in what is termed nonroutine parameters (e.g., residual reactants and residual catalysts). Variation of these parameters may not be commonly measured by the manufacturer.

So in the majority of cases, robust drug products are successfully developed and manufactured to manage such excipient variability. Failure, however, to understand and control excipient variability has indeed led to some serious quality issues.

FDA, for example, has spoken publicly about excipient variability and its relation to drug-product recalls from the market. It is clear that some existing development and manufacturing practices can fail to ensure that medicines of the appropriate quality standards that are routinely produced. Furthermore, demonstrating quality by testing does not prevent these substandard drug products from entering the market. Obviously, quality failures, including those related to excipient variability, can have serious consequences to the manufacturer in terms of financial and reputational damage. Ultimately, the end user, the patient, is put at risk.

Substandard drug products reaching the patient can impact safety and efficacy. And even those that are captured and rejected by quality control or those recalled from the market can lead to drug shortages. This, again, impacts the patient. So, with increasing public focus upon the pharmaceutical industry and regulators alike, it is clear that managing excipient variability will be an area of increasing industry importance.

It is critical, therefore, for excipient manufacturers and vendors to closely collaborate with the developer to better reduce the risks of quality failures. This is important from early on in the drug product's development, whereby knowledge and experience of the excipient can proactively support robust formulation design and efficient manufacturing control. Failure to account for normal excipient variability can lead to the design and development of nonrobust formulations. Unfortunately, this can necessitate tighter excipient-specification test limits, batch selection, or even custom manufacture to control the performance of the finished drug product.

It must be recognized that, in some instances, the ability of the excipient manufacturer to meet such requirements may not be easily achieved, if achievable at all. This, therefore, presents additional risk and cost to the overall product.

It also is important to consider the interplay of all variables including those of the API and the manufacturing process. The use of risk assessment is helpful to identify those primary variables that may affect the drug product's critical quality attributes.

So, the ability of the developer to determine the effects and interactions of excipient material attributes, along with API and processing parameters, using approaches such as design of experiments, can provide valuable insight into their true criticality upon drug-product quality.

Using QbD, therefore, presents an opportunity to ensure quality is built in by design. Early collaboration by all stakeholders can better ensure that the potential risks of normal excipient variability can be efficiently designed out by our prior knowledge and available tools.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here